According to Peking University Pharmaceutical's announcement, Dongxinan Synthetic Pharmaceutical Group Co., Ltd., which holds more than 5% of its shares, was judicially enforced due to a financing and securities transaction dispute. From October 9 to October 15, 2026, the company's shares were passively reduced by 5.966 million shares through bulk transactions, accounting for 1% of the company's total share capital. After this change in equity, Southwest Synthetic's total holdings of the company's shares fell from 20.00% to 19.00% of the total share capital, and the equity change hit an integer multiple of 1%. This judicial enforcement has not yet been completed, and it has not had a significant adverse impact on the company's production and operation, financial situation and governance structure.

According to Peking University Pharmaceutical's announcement, Dongxinan Synthetic Pharmaceutical Group Co., Ltd., which holds more than 5% of its shares, was judicially enforced due to a financing and securities transaction dispute. From October 9 to October 15, 2026, the company's shares were passively reduced by 5.966 million shares through bulk transactions, accounting for 1% of the company's total share capital. After this change in equity, Southwest Synthetic's total holdings of the company's shares fell from 20.00% to 19.00% of the total share capital, and the equity change hit an integer multiple of 1%. This judicial enforcement has not yet been completed, and it has not had a significant adverse impact on the company's production and operation, financial situation and governance structure.